I Kr Inhibitors
2 drugsAbout I Kr
I Kr, the rapidly activating delayed rectifier potassium current, is crucial for the repolarization phase of the cardiac action potential. Blocking IKr prolongs the action potential duration and the QT interval, which can be both therapeutically beneficial and potentially fatal.
IKr is a significant target in cardiovascular drug development, though there is currently no genetic evidence directly linking IKr to specific diseases. Excessive IKr blockade can lead to Torsades de Pointes, requiring careful drug consideration and monitoring.
Two FDA-approved small molecule drugs, DOFETILIDE (Aurobindo Pharma) and TIKOSYN (Pfizer), target IKr in the cardiovascular therapeutic area for managing heart rhythm disorders. These drugs were approved in 1999 and 2019, respectively.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Metastatic Melanoma with only 1 trials.
Top I Kr Drugs
The competitive landscape includes Aurobindo Pharma and Pfizer, each with approved drugs.
Low market concentration suggests relatively low barriers to entry for new competitors.
I Kr Drug Modality Landscape
Modalities
Routes of Administration
I Kr is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or gene therapies represents a whitespace opportunity.
I Kr Clinical Trials 5 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 4 | 1 | 0 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
I Kr Drug Approval Timeline (1999 - 2019)
The approval timeline spans 21 years, with the first drug approved in 1999 and the most recent in 2019.
The slow approval rate indicates potential challenges in developing IKr-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 13 clinical trials targeting I Kr.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities